241 related articles for article (PubMed ID: 35570499)
1. New Insights and Implications of Natural Killer Cells in Parkinson's Disease.
Menees KB; Lee JK
J Parkinsons Dis; 2022; 12(s1):S83-S92. PubMed ID: 35570499
[TBL] [Abstract][Full Text] [Related]
2. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
3. The role of natural killer cells in Parkinson's disease.
Earls RH; Lee JK
Exp Mol Med; 2020 Sep; 52(9):1517-1525. PubMed ID: 32973221
[TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA sequencing of CSF reveals neuroprotective RAC1
Guan Q; Liu W; Mu K; Hu Q; Xie J; Cheng L; Wang X
Front Immunol; 2022; 13():992505. PubMed ID: 36211372
[TBL] [Abstract][Full Text] [Related]
5. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
7. Pathological Role of Natural Killer Cells in Parkinson's Disease: A Systematic Review.
Zhang L; Zhang Y; Fan D
Front Aging Neurosci; 2022; 14():890816. PubMed ID: 35663564
[TBL] [Abstract][Full Text] [Related]
8. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease.
Tan Y; Sgobio C; Arzberger T; Machleid F; Tang Q; Findeis E; Tost J; Chakroun T; Gao P; Höllerhage M; Bötzel K; Herms J; Höglinger G; Koeglsperger T
Acta Neuropathol; 2020 Feb; 139(2):319-345. PubMed ID: 31768670
[TBL] [Abstract][Full Text] [Related]
9. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
10. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
11. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
12. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease.
Barrenschee M; Zorenkov D; Böttner M; Lange C; Cossais F; Scharf AB; Deuschl G; Schneider SA; Ellrichmann M; Fritscher-Ravens A; Wedel T
Acta Neuropathol Commun; 2017 Jan; 5(1):1. PubMed ID: 28057070
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
14. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts.
Teil M; Arotcarena ML; Faggiani E; Laferriere F; Bezard E; Dehay B
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138193
[TBL] [Abstract][Full Text] [Related]
15. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.
Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW
Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147
[TBL] [Abstract][Full Text] [Related]
17. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
18. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
20. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]